Biotech Values

[mouton29]

<<i don't know if you can call this report high quality. while the uncertainty regarding tL may continue to weigh on shares this year, and i can't really argue with their comments on mC (although mnta is hopeful for a 2011 trial still) or on the (lack of) valuation for m118, there is a gross error>>

If they are truly assuming zero revenue from mL after April 2011, zero value for M118 and the TEVA patent trial not even starting till 2012, I am curious how can they get to a discounted value per share of $21.

Mqybe when they says "We continue to model an April 1 Teva launch, " that just means exactly that, they model it, but are not assuming a 100% probability of that outcome. That would be appropriate given their statement that "Teva’s latest FDA Warning Letter suggests that [April approval] may be optimistic".